Across TCGA pan-cancer cohorts, COX7B2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated COX7B2 data layer compared with 16 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher COX7B2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated COX7B2 expression acts as an unfavorable survival marker.
BLCA are the cancer types where COX7B2 Mutation most reproducibly stratifies survival.